Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL831505 | 0.79 | HSP90AA1 (0.44) | CA2CA1KMT2AL3MBTL1MEN1 | |
| SCHEMBL831449 | 0.79 | CA2 (0.54) | CA2CA1CA4L3MBTL1MAPT | |
| SCHEMBL829598 | 0.79 | CA2 (0.40) | CA2CA1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL830991 | 0.79 | CA2 (0.40) | CA2CA1KMT2AMEN1NPC1 | |
| SCHEMBL829683 | 0.76 | CA2 (0.57) | CA2CA1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL831810 | 0.72 | NPC1 (0.40) | CA2KDM4EKMT2ANPC1GAA | |
| SCHEMBL830556 | 0.69 | CA2 (0.54) | CA2CA1CA4L3MBTL1MAPT | |
| SCHEMBL831074 | 0.69 | CA2 (0.36) | CA2CA1KDM4EALDH1A1KMT2A | |
| SCHEMBL13495923 | 0.69 | BACE1 (0.57) | CA2CA1CA4KDM4EALDH1A1 | |
| SCHEMBL29954520 | 0.67 | MGLL (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-10-04 | — | — | US | claimed |
| EP-1765804-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2005123077-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-12-29 | — | — | WO | claimed |
| US-8143428-B2 | Heteroaryl sulfones and sulfonamides and therapeutic uses thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | SULT1E1, STS, CCNE1 | CA2 2552/4885CA1 3859/4885CA4 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.